SBRT Combined With Adbelimumab and Apatinib for Perioperative and Conversion Therapy of Hepatocellular Carcinoma

NCT06538935 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

80

Enrollment

OTHER_GOV

Sponsor class

Conditions

Hepatocellular Carcinoma
SBRT
Immune Checkpoint Blockade
Tyrosine Kinase Inhibitor

Interventions

DRUG: adbelimumab
PROCEDURE: SBRT
DRUG: apatinib

Sponsor

Fujian Cancer Hospital